Long-Term Outcomes of the Flixene Vascular Graft Used for Haemodialysis.
| Title: | Long-Term Outcomes of the Flixene Vascular Graft Used for Haemodialysis. |
|---|---|
| Authors: | He B; Western Australia (WA) Liver and Kidney Transplant Service, Sir Charles Gairdner Hospital, University of Western Australia, Perth, AUS.; Department Renal Surgery and Transplant, Austin Hospital, Victoria, AUS.; Department Renal Surgery and Transplant, Alfred Hospital, Monash University, Prahran, AUS.; Tailor D; Western Australia (WA) Liver and Kidney Transplant Service, Sir Charles Gairdner Hospital, Perth, AUS.; Ng ZQ; Western Australia (WA) Liver and Kidney Transplant Service, Sir Charles Gairdner Hospital, Perth, AUS.; Samuelson S; Department of Radiology, Sir Charles Gairdner Hospital, Perth, AUS.; Nadkarni S; Department of Radiology, Sir Charles Gairdner Hospital, Perth, AUS.; Van Myk M; Department of Radiology, Sir Charles Gairdner Hospital, Perth, AUS.; Ferguson J; Department of Radiology, Sir Charles Gairdner Hospital, Perth, AUS.; Tibballs J; Department of Radiology, Sir Charles Gairdner Hospital, Perth, AUS.; Chan D; Department of Nephrology, Sir Charles Gairdner Hospital, Perth, AUS. |
| Source: | Cureus [Cureus] 2021 Feb 20; Vol. 13 (2), pp. e13459. Date of Electronic Publication: 2021 Feb 20. |
| Publication Type: | Journal Article |
| Language: | English |
| Journal Info: | Publisher: Cureus, Inc Country of Publication: United States NLM ID: 101596737 Publication Model: Electronic Cited Medium: Print ISSN: 2168-8184 (Print) Linking ISSN: 21688184 NLM ISO Abbreviation: Cureus Subsets: PubMed not MEDLINE |
| Imprint Name(s): | Original Publication: Palo Alto, CA : Cureus, Inc. |
| Abstract: | Introduction The Flixene™ vascular graft (Maquet-Atrium Medical, Hudson, NH) has emerged as a new generation synthetic graft, which allows for early needling for haemodialysis. Most studies have shown satisfactory early results. The aim of this study is to report on long-term outcomes of the Flixene graft over eight years in a cohort of patients. Methods From February 2011 to September 2019, 61 patients had 64 arteriovenous graft fistulas (AVGs) by using the Flixene grafts. The median patient age was 67 years; the male to female ratio was 30:31. Diabetes was the reason for the majority of kidney failures (57%). The configuration of the grafts used was mostly upper arm straight AVG. The primary patency rate, secondary patency rate, and surgical complications were assessed. Results In a median follow-up of three years (interquartile range (IQR): 2 - 6), 36 of the AVGs required a fistulogram. Venous side stenosis was the most common cause of high venous pressure or AVG occlusion in 97%. The one-year primary patency rate was 30%. The secondary patency rate was 94.8%, 83.7%, and 77.7% at one, three, and five years, respectively. The longest functional AVG was observed for up to seven years. Conclusions This study has shown satisfactory long-term results of the Flixene graft used for hemodialysis. The Flixene graft could be needled within 72 hours without increased complications, which allows the creation of an AVG under an emergency setting to avoid the placement of a central venous catheter (CVC). This strategy should be advocated in future clinical practice.; (Copyright © 2021, He et al.) |
| Competing Interests: | The authors have declared that no competing interests exist. |
| References: | Adv Chronic Kidney Dis. 2015 Nov;22(6):431-7. (PMID: 26524947); Clin J Am Soc Nephrol. 2019 Jun 7;14(6):954-961. (PMID: 30975657); Am J Kidney Dis. 2014 Mar;63(3):464-78. (PMID: 24183112); Biomech Model Mechanobiol. 2020 Apr;19(2):713-722. (PMID: 31679093); J Vasc Access. 2020 Nov;21(6):883-891. (PMID: 32141378); Am J Physiol Renal Physiol. 2019 May 1;316(5):F794-F806. (PMID: 30785348); Am J Surg. 2014 Nov;208(5):800-805. (PMID: 24811929); J Vasc Surg. 2019 Mar;69(3):883-889. (PMID: 30528400); J Vasc Access. 2018 Jan;19(1):45-51. (PMID: 29148001); Semin Dial. 2011 Sep-Oct;24(5):515-24. (PMID: 21906166); Trans Am Soc Artif Intern Organs. 1976;22:382-7. (PMID: 951854); Am J Kidney Dis. 2004 Nov;44(5):779-91. (PMID: 15492943); J Vasc Surg. 2016 Jul;64(1):155-62. (PMID: 27066945); Clin J Am Soc Nephrol. 2015 Dec 7;10(12):2255-62. (PMID: 25883073); J Vasc Surg. 2015 Jul;62(1):128-34. (PMID: 25770983); J Vasc Surg. 2002 Mar;35(3):603-10. (PMID: 11877717); J Vasc Interv Radiol. 2003 Sep;14(9 Pt 2):S433-42. (PMID: 14514859); J Vasc Access. 2017 Mar 21;18(2):109-113. (PMID: 28165572); J Vasc Interv Radiol. 2013 Sep;24(9):1289-94. (PMID: 23871694); Am J Kidney Dis. 2012 Dec;60(6):983-9. (PMID: 22824354); Clin J Am Soc Nephrol. 2009 Jan;4(1):86-92. (PMID: 18945990); Am J Kidney Dis. 2009 Nov;54(5):912-21. (PMID: 19748717); J Vasc Access. 2019 Mar;20(2):123-127. (PMID: 29843554); Am J Kidney Dis. 2011 Aug;58(2):243-7. (PMID: 21458898); J Vasc Surg. 2019 Oct;70(4):1235-1241. (PMID: 31147122); J Vasc Access. 2016 Mar;17 Suppl 1:S75-8. (PMID: 26951911); Clin J Am Soc Nephrol. 2010 Dec;5(12):2348-54. (PMID: 21030576); Am J Kidney Dis. 2007 Aug;50(2):289-95. (PMID: 17660030); Clin J Am Soc Nephrol. 2017 Jun 7;12(6):955-964. (PMID: 28522650); Am Surg. 2014 Feb;80(2):155-8. (PMID: 24480215) |
| Contributed Indexing: | Keywords: arteriovenous fistula; arteriovenous graft fistula; central venous catheter (cvc); flixene graft; haemodialysis access; primary patency rate; secondary patency rate |
| Entry Date(s): | Date Created: 20210329 Latest Revision: 20210330 |
| Update Code: | 20260130 |
| PubMed Central ID: | PMC7984851 |
| DOI: | 10.7759/cureus.13459 |
| PMID: | 33777548 |
| Database: | MEDLINE |
Journal Article